International Stem Cell Corporation (OTC: ISCO) focuses on
utilizing patented human parthenogenetic stem cells (hPSC), developed from
unfertilized embryos, to treat Parkinson’s, retinal, and liver diseases where
replacing dead and dying cells with new ones seems most effective. However, the
road to commercialization and FDA approval is a long one. Therefore, the
company has two wholly-owned subsidiaries that generate money in the meantime:
Lifeline Skin Care, Inc. and Lifeline Cell Technology, LLC.
The first, Lifeline Skin Care, Inc., develops, produces, and
markets a line of anti-aging cosmetic skin care products. These products use
the company’s scientific rejuvenation breakthrough of non-embryonic stem cells
to improve the look and feel of skin. These products include neck and eye
firming creams, moisturizers, cleansers, and more. Sold all over the world,
this cosmetic line promises youthful and healthy looking skin.
The second, Lifeline Cell Technology, LLC, develops,
manufactures, and sells human cell culture products along with optimized
reagents for laboratory research purposes. For example, the company offers
VascuLife®SMC, a human smooth muscle cell medium optimized for the culture of
human smooth muscle cells. This provides 15 population doublings at high growth
rates. The company also sells Normal Human Mammary Epithelial Cells (HMEC) that
provide a serum-free culture model for research on breast cancer, carcinogen
screening, and other areas of breast research. All of Lifeline Cell Technology
products are rigorously tested to the highest degree for maximum laboratory
research operations.
In a news release, Andrey Semechkin, Ph.D., CEO, and
co-chairman of ISCO recently stated, “We are maintaining our position as a
leader in the regenerative medicine field and the overall operating income of
our biomedical businesses continues to grow.” The company continues to
manufacture and market its proprietary innovations while advancing developments
in treatments of various diseases using stem cells.
To find out what the buzz is all about, visit
www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
